Advertisement
Advertisement

PYXS

PYXS logo

Pyxis Oncology, Inc. Common Stock

3.89
USD
Sponsored
+0.33
+9.12%
Sep 04, 15:59 UTC -4
Closed
exchange

After-Market

3.86

-0.03
-0.77%

PYXS Earnings Reports

Positive Surprise Ratio

PYXS beat 9 of 20 last estimates.

45%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.29
Implied change from Q2 26 (Revenue/ EPS)
--
/
-27.50%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-17.14%

Pyxis Oncology, Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, PYXS reported earnings of -0.40 USD per share (EPS) for Q2 26, missing the estimate of -0.36 USD, resulting in a -10.99% surprise. Revenue reached --, compared to an expected 22.32 thousand, with a -100.00% difference. The market reacted with a -7.42% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.29 USD, with revenue projected to reach -- USD, implying an decrease of -27.50% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
BioLineRX Ltd
Report Date
Aug 31, 2026 For Q2 26
Estimate
-
Actual
-$0.77
Surprise
-
logo
Galmed Pharmaceuticals Ltd.
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.18
Actual
$2.86
Surprise
+189.87%
FAQ
For Q2 2026, Pyxis Oncology, Inc. Common Stock reported EPS of -$0.40, missing estimates by -10.99%, and revenue of $0.00, -100% below expectations.
The stock price moved down -7.42%, changed from $3.37 before the earnings release to $3.12 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 7 analysts, Pyxis Oncology, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement